The Role of Interferons in Viral Infections in Immune Compromised Patients

  • R. T. Schooley
  • M. S. Hirsch
  • R. H. Rubin
  • K. Cantell
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)


Herpesgroup viruses remain cause of morbidity among renal allograft recipients. Over the past several years the development of antiviral drugs such as adenine arabinoside and acyclovir have resulted in major improvements in management of herpes simplex (HSV) and varicella zoster virus (VZV) infections (1). Cytomegalovirus (CMV) and Epstein-Barr virus (EBV), however, continue to contribute to the morbidity of renal transplantation (2–6). CMV infection has several effects on the host. Between 30 and 40% of all renal allograft recipients develop clinically apparent CMV syndromes and 2–3% will have fatal infections. CMV infection following transplantation may be either primary or due to reactivation of latent virus. Primary infection occurs in 60–70% of CMV seronegative renal allograft recipients who receive grafts from CMV seropositive donors. Reactivation of CMV occurs in approximately 60% of CMV seropositive recipients. Because most adult allograft recipients in the United States are CMV seropositive, primary CMV infections are less common than reactivation infections, but may be associated with more morbidity when they are observed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hirsch MS, Schooley RT. Treatment of herpesvirus infections. N Engl J Med 1983; 309: 963.PubMedCrossRefGoogle Scholar
  2. 2.
    Glenn J. Cytomegalovirus infections following renal transplantation. Rev Infect Dis 1981; 3: 1151–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Marker SC, Howard RJ, Simmons RL, et al. Cytomegalovirus infection: A quantitative prospective study of three hundred twenty consecutive renal transplants. Surgery 1981; 89: 660–71.PubMedGoogle Scholar
  4. 4.
    Harwood AR, Osoba D, Hofstader SL, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979; 67: 759–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1980; 305: 57–63.CrossRefGoogle Scholar
  6. 6.
    Hanto DW, Frizzera G, Gejl-Peczalaska J, et al. The Epstein-Barr virus in the pathogenesis of post transplant lymphoma. Transplant Proc 1981; 13: 756–60.PubMedGoogle Scholar
  7. 7.
    Ho M. Cytomegalovirus: Biology and infection. New York, Plenum, 1982.CrossRefGoogle Scholar
  8. 8.
    Carney WP, Hirsch MS. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis 1981; 144: 47–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Carney WP, Rubin RH, Hoffman RA, Hansen WP, Healey K, Hirsch MS. Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 1981; 126: 2114–6.PubMedGoogle Scholar
  10. 10.
    Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983; 308: 307–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Colvin RB, Cosimi AB, Burton RC, et al. Circulating T-cell subsets in human renal allograft recipients: The OKT4+/OKT8+ cell ratio correlates with reversibility of graft injury. Presented at the 9th International Congress of the Transplantation Society, Brighton, United Kingdom, 1982 August 23–27.Google Scholar
  12. 12.
    Cheesemen SH, Henle W, Rubin R, et al. Epstein-Barr virus infection in renal transplant recipients: Effects of antithymocyte globuline and interferon. Ann Intern Med 1980; 93: 39–42.CrossRefGoogle Scholar
  13. 13.
    Cantell K, Hirvonen S, Kauppinen H-L, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78: 29–38.PubMedGoogle Scholar
  14. 14.
    Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981; 78: 499–505.PubMedGoogle Scholar
  15. 15.
    Cheeseman SH, Rubin RH, Stewart JA, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979; 30: 1345–9.CrossRefGoogle Scholar
  16. 16.
    Reedman BM, Klein G. Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 1973; 11: 499–520.PubMedCrossRefGoogle Scholar
  17. 17.
    Henle G, Henle W. Immunofluorescence in cells derived from Burkitt’s lymphoma. J Bacteriol 1966; 91: 1248–56.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Henle G, Henle W, Klein G. Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer 1971; 8: 272–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977; 24: 458–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. N Engl J Med 1983; 308: 1489–93.PubMedCrossRefGoogle Scholar
  21. 21.
    Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer. JAMA 1982; 247: 1718–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Scott GM, Phillpotts RJ, Wallace J, Gauci CL, Greiner J, Tyrrell DAJ. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichiacoli. Lancet 1982;ii:186–8.Google Scholar
  23. 23.
    Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 1981; 143: 585–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Zaia JA, Levin MJ, Leszczynski J, Wright GG, Grady GF. Cytomegalovirus immune globulin: production from selected normal donor blood. Transplantation 1979; 27: 66–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Andrus CH, Betts RF, May AG, Freeman RB. Cytomegalovirus infection blocks the beneficial effect of pretransplant blood transfusion on renal allograft survival. Transplantation 1979; 28: 451–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • R. T. Schooley
  • M. S. Hirsch
  • R. H. Rubin
  • K. Cantell

There are no affiliations available

Personalised recommendations